789 related articles for article (PubMed ID: 35293796)
1. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
[TBL] [Abstract][Full Text] [Related]
2. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
3. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
[TBL] [Abstract][Full Text] [Related]
4. Current Status and Perspectives of Therapeutic Antibodies Targeting the Spike Protein S2 Subunit against SARS-CoV-2.
Yamamoto Y; Inoue T
Biol Pharm Bull; 2024; 47(5):917-923. PubMed ID: 38692869
[TBL] [Abstract][Full Text] [Related]
5. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.
Mariotti S; Capocefalo A; Chiantore MV; Iacobino A; Teloni R; De Angelis ML; Gallinaro A; Pirillo MF; Borghi M; Canitano A; Michelini Z; Baggieri M; Marchi A; Bucci P; McKay PF; Acchioni C; Sandini S; Sgarbanti M; Tosini F; Di Virgilio A; Venturi G; Marino F; Esposito V; Di Bonito P; Magurano F; Cara A; Negri D; Nisini R
Front Immunol; 2021; 12():750386. PubMed ID: 34764961
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 spike S2-specific neutralizing antibodies.
Li CJ; Chang SC
Emerg Microbes Infect; 2023 Dec; 12(2):2220582. PubMed ID: 37254830
[TBL] [Abstract][Full Text] [Related]
8. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
9. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
10. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.
Gao X; Fan L; Zheng B; Li H; Wang J; Zhang L; Li J; Zhu F
Hum Vaccin Immunother; 2022 Nov; 18(5):2055373. PubMed ID: 35417303
[TBL] [Abstract][Full Text] [Related]
11. A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
Hua RH; Zhang SJ; Niu B; Ge JY; Lan T; Bu ZG
Microbiol Spectr; 2023 Aug; 11(4):e0119023. PubMed ID: 37306579
[TBL] [Abstract][Full Text] [Related]
12. Novel S2 subunit-specific antibody with broad neutralizing activity against SARS-CoV-2 variants of concern.
Heo CK; Lim WH; Yang J; Son S; Kim SJ; Kim DJ; Poo H; Cho EW
Front Immunol; 2023; 14():1307693. PubMed ID: 38143750
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies for the prevention and treatment of COVID-19.
Du L; Yang Y; Zhang X
Cell Mol Immunol; 2021 Oct; 18(10):2293-2306. PubMed ID: 34497376
[TBL] [Abstract][Full Text] [Related]
14. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain.
Niu L; Wittrock KN; Clabaugh GC; Srivastava V; Cho MW
Front Immunol; 2021; 12():647934. PubMed ID: 33995366
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
16. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants.
Jeong BS; Cha JS; Hwang I; Kim U; Adolf-Bryfogle J; Coventry B; Cho HS; Kim KD; Oh BH
MAbs; 2022; 14(1):2021601. PubMed ID: 35030983
[TBL] [Abstract][Full Text] [Related]
17. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
18. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.
Mittal A; Khattri A; Verma V
PLoS Pathog; 2022 Feb; 18(2):e1010260. PubMed ID: 35176090
[TBL] [Abstract][Full Text] [Related]
19. Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2.
Wang B; Xu H; Liang ZT; Zhao TN; Zhang X; Peng TB; Wang YC; Su XD
Int J Biol Macromol; 2023 Feb; 227():896-902. PubMed ID: 36528147
[TBL] [Abstract][Full Text] [Related]
20. Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.
Lai GC; Chao TL; Lin SY; Kao HC; Tsai YM; Lu DC; Chiang YW; Chang SY; Chang SC
Antiviral Res; 2022 Apr; 200():105290. PubMed ID: 35296418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
